Three hospital systems across England have initiated a live clinical trial of AI technology aimed at detecting and grading prostate cancer. The trial, known as ARTICULATE PRO, is led by the University of Oxford in partnership with Paige, a front-runner in clinical AI applications for cancer diagnosis.
The three participating hospitals – North Bristol Trust Southmead Hospital, University Hospitals Coventry and Warwickshire, and Oxford University NHS Foundation Trust – have integrated Paige’s AI technology into their standard care protocols. This collaborative trial seeks to assess the potential of AI in enhancing patient outcomes amidst a surge in prostate cancer cases.
Professor Clare Verrill, OUH Cellular Pathology Consultant, Associate Professor, and Principal Investigator of ARTICULATE PRO, stated, “The primary focus of ARTICULATE PRO is on patients. Our objective is to leverage powerful AI technology to ensure their maximum benefit in a safe and effective manner.
“By implementing The Paige Prostate Suite across multiple sites, we can systematically evaluate the advantages for patients in real clinical settings.”
The Prostate Suite – the AI system under trial – is designed to support pathologists in identifying, grading, and measuring tumors in prostate biopsies and tissue samples. Pathologists at the three hospitals are examining how this AI technology influences their clinical decision-making, pathology services, and resource utilization in practical scenarios.
Dr Jon Oxley, Uropathologist and Bristol lead of ARTICULATE PRO, remarked, “Having researched prostate cancer and its progression for over 25 years, it is a significant milestone that Paige’s AI applications have reached a level of validation and performance enabling safe and effective live clinical utilization.
“Integrating Paige Prostate Suite with our standard care has the potential to enhance efficiency and enhance result reproducibility for patients.”
This study stands out for its implementation across hospitals using different digital pathology scanners and information systems, catering to diverse patient demographics. This diversity allows for a comprehensive evaluation of how Paige’s AI technology can best serve patients, histopathologists, and hospital systems in prostate cancer diagnosis.
Dr Bidisa Sinha, Uropathologist at University Hospitals Coventry and Warwickshire, added, “We believe AI can enhance the accuracy and consistency of cancer grading and aid in detecting small cancerous areas that may be overlooked.
“This groundbreaking research at UHCW positions us as a global leader in digital and computational pathology.”
The ARTICULATE PRO study is funded by the Accelerated Access Collaborative (AAC) Artificial Intelligence in Health and Care Award, overseen by the Department of Health and Social Care.
As prostate cancer rates continue to rise, the incorporation of AI in diagnosis could potentially lead to earlier detection, more precise grading, and ultimately improved patient outcomes. The findings from this trial could set the stage for broader adoption of AI in cancer diagnosis in the UK and beyond.
(Image Credit: Paige)
See also: AI could unleash £119 billion in UK productivity
Want to learn more about AI and big data from industry leaders? Check out AI & Big Data Expo happening in Amsterdam, California, and London. This comprehensive event is co-located with other leading events including Intelligent Automation Conference, BlockX, Digital Transformation Week, and Cyber Security & Cloud Expo.
Explore other upcoming enterprise technology events and webinars powered by TechForge here.
